| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 11, 2026 | AnaCardio Announces Phase 1b/2a GOAL-HF1 Results of AC01 Demonstrating Favorable Safety and Sustained Improvements in Cardiac Function on Top of Standard-of-Care Therapy in HFrEF | AnaCardio Announces Phase 1b/2a GOAL-HF1 Results of AC01 Demonstrating Favorable Safety and Sustained Improvements in Cardiac Function on Top of Standard-of-Care Therapy in HFrEF
Mon, May 11, 2026 08:00 CET Report this content
STOCKHOLM, Sw... |
| Mar 26, 2026 | AnaCardio’s AC01 Phase 1b/2a HFrEF Study Selected for Late-Breaking Science Presentation at the Heart Failure 2026 Congress | AnaCardio’s AC01 Phase 1b/2a HFrEF Study Selected for Late-Breaking Science Presentation at the Heart Failure 2026 Congress
Thu, Mar 26, 2026 08:00 CET Report this content
STOCKHOLM, Sweden – March 26, 2026 – AnaCardio today announces that ... |
| Mar 11, 2026 | AnaCardio announces issuance of U.S. patent for AC01, strengthening protection into the 2040s | AnaCardio announces issuance of U.S. patent for AC01, strengthening protection into the 2040s
Wed, Mar 11, 2026 09:00 CET Report this content
Stockholm, Sweden and Lugano, Switzerland, March 11, 2026 - AnaCardio, a clinical-stage biopharmac... |
| Feb 27, 2026 | InVirtuoLabs closes R&D agreement with Helsinn |
Under the terms of the agreement, Helsinn will provide InVirtuoLabs with access to a proprietary library of structurally diverse compounds, including validated hits with confirmed biological activity against an undisclosed therapeutic targ... |
| Dec 10, 2025 | AnaCardio Reports Strong Phase 2a Topline Results for AC01 in patients with heart failure and reduced ejection fraction (HFrEF); Paving the Way for Rapid Advancement to Phase 2b | AnaCardio Reports Strong Phase 2a Topline Results for AC01 in patients with heart failure and reduced ejection fraction (HFrEF); Paving the Way for Rapid Advancement to Phase 2b
Wed, Dec 10, 2025 08:00 CET Report this content
December 10, 2... |
| Sep 16, 2025 | AnaCardio Announces Completion of Target Enrollment in Phase 2a Study of AC01 in Heart Failure; Results Expected Year-end 2025 | AnaCardio Announces Completion of Target Enrollment in Phase 2a Study of AC01 in Heart Failure; Results Expected Year-end 2025
Tue, Sep 16, 2025 09:00 CET Report this content
Stockholm, Sweden, September 16, 2025 – AnaCardio, a clinical-sta... |
| Sep 2, 2025 | AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer | AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer
Tue, Sep 02, 2025 09:00 CET Report this content
Stockholm, Sweden, September 2, 2025 - AnaCardio, a Swedish clinical-stage biopharmaceutica... |
| Jul 17, 2025 | AnaCardio announces positive scientific advice from the FDA and EMA, establishing a favourable development path for AC01 treatment of chronic HFrEF | AnaCardio announces positive scientific advice from the FDA and EMA, establishing a favourable development path for AC01 treatment of chronic HFrEF
Thu, Jul 17, 2025 09:00 CET Report this content
Alignment reached with both the FDA and EMA ... |
| Mar 13, 2025 | AnaCardio receives patent grant in Europe for AC01 | AnaCardio receives patent grant in Europe for AC01
Thu, Mar 13, 2025 09:00 CET Report this content
Stockholm, Sweden and Lugano, Switzerland, March 13, 2025 - AnaCardio, a clinical-stage biopharmaceutical company developing novel contractil... |
| Feb 25, 2025 | AnaCardio reports first patient dosed in the phase 2a study evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF) | AnaCardio reports first patient dosed in the phase 2a study evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF)
Tue, Feb 25, 2025 09:00 CET Report this content
February 25, 2025, Stockholm, Sweden - AnaCardi... |
| Feb 20, 2025 | €2.85 million to accelerate AI in drug discovery |
At the heart of InVirtuoLabs' innovation is the Next Generation Virtual Lab, a proprietary platform that uses AI and molecular modeling to identify and optimize drugs with proven precision. This approach allows for doubling success rates c... |
| Jan 11, 2025 | AnaCardio's €19 Million Leap: A New Dawn for Heart Failure Treatment | In the world of biopharmaceuticals, every funding round can feel like a heartbeat—vital and pulsating with potential. AnaCardio, a clinical-stage startup based in Stockholm, has just secured €19 million (approximately USD 19 million) to adv... |
| Jan 9, 2025 | AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure | AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure
Thu, Jan 09, 2025 09:00 CET Report this content
Reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ... |
| Apr 13, 2023 | AnaCardio reports first patient dosed in the GOAL-HF1 study, a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK | AnaCardio reports first patient dosed in the GOAL-HF1 study, a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK
Thu, Apr 13, 2023 12:00 CET Report this content
Solna, Sweden and Lugano, Switzerland, April 13, 2022 - An... |
| Jan 24, 2023 | Helsinn and Immedica enter exclusive partnership for commercialization of cancer supportive care products in core European markets | Helsinn and Immedica enter exclusive partnership for commercialization of cancer supportive care products in core European markets
Tue, Jan 24, 2023 09:00 CET Report this content
LUGANO, Switzerland and STOCKHOLM, Sweden – January 24, 2023 ... |
| Sep 1, 2022 | Juniper Biologics Pte. Ltd. signs exclusive license agreement with Helsinn Healthcare SA for LEDAGA® (chlormethine) in Australia, Asia and the Middle East* | LUGANO, Switzerland, Sept. 1, 2022 /PRNewswire/ -- Helsinn Group ("Helsinn"), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, ... |
| May 4, 2022 | Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets* | LUGANO, Switzerland, and SINGAPORE, May 4, 2022 /PRNewswire/ -- Juniper Biologics Pte Ltd, a science-led healthcare company focused on researching, developing and commercializing novel therapies, and Helsinn Group, a fully integrated, globa... |
| Jun 21, 2021 | McKesson : TRUSELTIQ (infigratinib), FDA Approved for Treatment of Cholangiocarcinoma, Available at Biologics by McKesson | CARY, N.C., June 21, 2021-Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by QED Therapeutics, an affiliate of BridgeBio Pharma, Inc. (BridgeBio) and Helsinn Group,... |
| Mar 29, 2021 | Second 3B Future Health Fund launched | 3B FUTURE HEALTH GP S.a.r.l. launches the 3B Future Health Fund II. The Fund is focused on early-stage investment opportunities in areas of high unmet patient need and follows the success of 3B Future Health Fund I, formerly known as Helsin... |
| Mar 29, 2021 | Second 3B Future Health Fund launched | |
| Jul 14, 2020 | 3B Future Health Fund Announces New Investment in iOnctura | MONACO, PRINCIPALITY OF MONACO, 14 July 2020: 3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR, today announces that it has invested in iOnctura SA, a clinical stage biopharmaceutical company developing a pipel... |
| Jul 14, 2020 | iOnctura extends series A round to €20 million | iOnctura SA is a clinical-stage biopharmaceutical company developing a pipeline of next-generation molecules targeting cancer and fibrosis. The company’s lead programme, IOA-244, entered the clinic in Q1 2020 to clinically demonstrate for t... |
| Jul 14, 2020 | iOnctura extends series A round to €20 million | |
| Jan 31, 2020 | Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award | MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, January 31, 2020: Lyfebulb, a patient empowerment platform that connects patients with industry to support user-driven innovation toward solutions in chronic disease, and Helsinn, a Swi... |
| Jul 15, 2019 | Helsinn Investment Fund Announces First Exit | Luxembourg, 15 July 2019 Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient need, today announces the fund first exit since launching in 2016. |
| Mar 19, 2019 | Winners of the Second Annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology Announced | MONACO, PRINCIPALITY OF MONACO and NEW YORK, NY, MARCH 19, 2019: |
| Feb 19, 2019 | Helsinn Investment Fund Invests €1 Million in Gain Therapeutics | Luxembourg, 19 February 2019: Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient need, today announces that it has made a €1 Million investment in Gain Therapeutics SA... |
| Apr 30, 2018 | NovellusDx Announces It Has Completed an Equity Financing of $6 Million | Jerusalem, Israel, 30 April 2018 – NovellusDx, the leader in functional genomics, today announced it has completed an equity financing of $6 million. The financing round is with the participation of Helsinn Investment Fund S.A. SICAR, par... |
| Mar 28, 2018 | Winners of the Inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology Announced | Lorenzo Pradella of GreenBone Ortho, srl has been selected from eleven finalists as the winner of the first-ever Lyfebulb-Helsinn Innovation Award in Oncology. |
| Mar 23, 2018 | Helsinn buys global rights for skin cancer drug from Actelion; Akebia reels in more cash for vadadustat; EMA slams Bevyxxa | → Swiss pharma group Helsinn is acquiring rights to skin cancer drug Valchlor (marketed as Ledaga in Europe) from Actelion Pharmaceuticals. The deal gets Helsinn worldwide rights to the rare disease drug, which is a topical... |
| Mar 14, 2018 | H.I.G. Joins Funding Round for On Target Labs | On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent dyes to improve cancer surgery, has secured an additional financing as part of its Series B capital raise which initially clo... |
| Mar 14, 2018 | On Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners, Elevate Ventures and Helsinn | WEST LAFAYETTE, Ind. 14 March 2018 – On Target Laboratories, Inc., a privately-held biotechnology company that is developing tumour-targeted fluorescent dyes to improve cancer surgery, has secured additional financing as part of its Serie... |
| Jan 30, 2018 | Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement | Lugano, Switzerland, 30 January 2018 – Helsinn International Services, Sarl, a Monaco-based affiliate of the Swiss Pharmaceutical Group focused on building quality cancer care products, and the Scientific Centre of Monaco (CSM), today ann... |
| Sep 5, 2017 | AMAL Therapeutics Raises €8 Million (CHF 8.8 Million) in First Closing of Series B Financing Round | Financing round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund |
| Sep 5, 2017 | Cancer vax biotech Amal grabs $10M round; Global Blood Therapeutics eyes PRV with new FDA designation | ⇨ Geneva-based Amal Therapeutics has picked up about $10 million in Series B money for its work on peptide-based cancer vaccines. Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund invested alo... |
| Jul 7, 2017 | Zealand Pharma blueprints an $86M IPO on Nasdaq as it maneuvers its way into PhIII | Copenhagen-based Zealand Pharma is following a clearly blazed trail from Europe to Nasdaq in search of an IPO that can help fund a pair of late-stage drugs.
Following the upbeat results for AC Immune (Switzerland) $ACIU and Ar... |
| Jun 16, 2017 | Helsinn Investment Fund Leads the Financial Round in GreenBone | Lugano, Switzerland, 16 June 2017: Helsinn Investment Fund S.A., a fund focused on early-stage investments in areas of high unmet patient need, today announces that it has made a Euro 2M investment in GreenBone, a privately-held developer o... |
| May 8, 2017 | Helsinn Investment Fund Invests in Aadi Bioscience | Luxembourg, 8 May 2017: Helsinn Investment Fund S.A, a fund focused on early-stage investment opportunities in areas of high unmet patient need, today announces that it has made a $2 million investment in Aadi Bioscience, Inc., U.S., a clin... |
| Oct 10, 2016 | Helsinn Investment Fund Invests £2.0 Million in QuantuMDx | Lugano, Switzerland, 10 October 2016: Helsinn Investment Fund S.A., a fund focused on early-stage investments in areas of high unmet patient need, today announces that it has made a £2.0 million investment in QuantuMDx Group, a privately-h... |
| Oct 10, 2016 | Helsinn Group Introduces Helsinn Investment Fund | Lugano, Switzerland, 10 October 2016: Helsinn, the Swiss Pharmaceutical Group focused on building quality cancer care, today introduces Helsinn Investment Fund S.A. (“the Fundâ€), a fund focused on early-stage investment opportunities in... |
| Oct 10, 2016 | Helsinn Investment Fund to Invest $3.5 Million in OncoResponse | Lugano, Switzerland, 10 October 2016: Helsinn Investment Fund S.A, a fund focused on early-stage investments in areas of high unmet patient need, today announces that on 23 September 2016, it made a $3.5 million investment in OncoResponse, ... |
| Aug 14, 2016 | Major drug partnership aims to develop new cancer drug | Helsinn assumes worldwide development costs and marketing rights for MEI Pharma’s drug and gains a foothold in the cancer therapeutics market. MEI receives $20 million in near-term payments with the potential for $444 million in various mil... |
| Aug 8, 2016 | Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development and Commercialisation of Pracinostat for the Treatment of Acute Myeloid Leukaemia and Other Haematologic Diseases | MEI Pharma to receive $20 million in near-term cash payments, plus up to $444 million in potential milestone payments as well as royalties on future sales. |
| Major drug partnership aims to develop new cancer drug | A recent cancer partnership worth hundreds of millions of dollars aims to develop a drug to contend with acute myeloid leukemia.
San Diego-based MEI Pharma has inked a deal with Swiss firm Helsinn to develop and market its HDAC (the class o... |